Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study
Primary Purpose
Analgesia, Critical Illness, Mechanical Ventilation
Status
Recruiting
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Nefopam
Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Sponsored by
About this trial
This is an interventional treatment trial for Analgesia focused on measuring Nefopam, Ketamine, Standard of care, Sedation, Critically ill, Mechanical ventilation, Propofol, Fentanyl, Midazolam, Delirium, Vasopressors.
Eligibility Criteria
Inclusion Criteria:
- Adult patients >18 years on mechanical ventilation and expected to need ventilatory support for the next 24 hours.
- Candidate for sedation and analgesia protocol
Exclusion Criteria:
- Pregnant and/or lactating woman.
- Has been intubated for duration longer than 12 hours in an intensive care unit.
- Proven or suspected acute primary brain lesion such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury.
- Proven or suspected spinal cord injury or other pathology that may result in permanent or prolonged weakness.
- Admission as a consequence of a suspected or proven drug overdose
- Mean arterial pressure (MAP) < 50 mmHg despite adequate resuscitation and vasopressor therapy at time of randomization.
- Death is deemed to be imminent or inevitable during this admission and either the attending physician, patient or substitute decision maker is not committed to active treatment.
- Patients with severe hepatic impairment (Child-Pugh class C) or end stage renal disease (ESRD) (creatinine clearance < 30 ml/min or on chronic hemodialysis) due to altered pharmacokinetics [20].
- Need for deep sedation such as administration of neuromuscular blockers.
- Convulsions or previous history of convulsions.
- Risk of urinary retention linked to uretroprostatic disorders.
- Risk of acute angle glaucoma.
- Known intolerance of or hypersensitivity to study medications or constituents.
Sites / Locations
- Cairo University Hospitals (Kasr Alainy)Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Nefopam group
Control group
Arm Description
Adjunct continuous infusion of nefopam plus standard of care in ICU for assessment and management of pain, sedation, and delirium. Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Outcomes
Primary Outcome Measures
Cumulative dose of fentanyl
To compare the cumulative dose of fentanyl
Secondary Outcome Measures
Richmond Agitation and Sedation Score (RASS)
To compare number of patients are in RASS score goal. RASS score minumum -5 (unarousable), maximun +4 (Combative). Goal RASS score from -1 (drowsy) to 0 (alert and calm).
pain score
To compare number of patients are in Pain score goal. If patient able to communicate we use the 0-10 numeric rating scale in a visual format (NRS-V), 0 indicate no pain and 10 indicate the worst pain imaginable.
For patient unable to communicate we use Critical care pain observation tool (CPOT) score, a score ≥3 indicate significant pain.
Duration of mechanical ventilation (MV)
To assess whether nefopam can help to shorten the of being mechanically ventilated.
vasopressor requirements
To compare vasopressors requirement
Hemodynamics
changes in Mean Arterial Pressure (MAP) mmHg
Hemodynamics
changes in Heart Rate (HR) beats/minute.
ICU length of stay (LOS)
To compare ICU LOS
Tracheostomy
Tracheostomy rate
Unplanned extubation (self-extubation)
Unplanned extubation date rate
Re-intubation
Re-intubation rate
Incidence of delirium
Rate of positive confusion assessment method for the ICU (CAM-ICU) score
Use of antipsychotics
Rate of using antipsychotics for confirmed ICU-acquired delirium
Use of physical restraint
Use of physical restraint
Mortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.
Mortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05071352
Brief Title
Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study
Official Title
Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2021 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The aim of this prospective, randomized, active control, double blinded study is to assess the effect and safety of continuous infusion nefopam in mechanically ventilated ICU patients compared to standard of care. It is being hypothesized that continuous infusion nefopam will reduce opioid use with acceptable safety profile compared to standard of care.
Detailed Description
Pain is defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage". Critically ill patients experience pain at rest and during standard caring procedures. Arterial catheter insertion, chest tube removal, wound drain removal, wound care, and turning are associated with the greatest increased pain intensity. Pain have short and long-term sequelae on critically ill patients. Short-term sequelae include impaired tissue oxygenation, impaired wound healing, and impaired immune functions. Long-term sequelae include chronic pain, Post-traumatic stress disorder (PTSD) symptoms, and a lower health-related quality of life.
The gold standard for pain assessment is patient's self-report of pain. For critically ill able to self-report pain the 0-10 numeric rating scale in a visual format (NRS-V) is the best to use. Unfortunately, a lot of critically ill patients are unable to communicate and self-report pain. So, using behavioral pain scales are suitable in this type of patients, Critical care pain observation tool (CPOT) demonstrates validity and reliability for monitoring pain in critical ill adult patient who are unable to self-report pain and in whom behaviors are observable. The 2018 Pain, Agitation/sedation, Delirium, Immobility, and Sleep disruption (PADIS) guideline panel suggests "using an assessment-driven, protocol-based, stepwise approach for pain and sedation management in critically ill adults" and state as a good practice statement "critically ill adults should be regularly assessed for delirium using a valid tool".
Opioids are a cornerstone in the management of pain in critically ill patient, but have a lot of negative consequences including constipation, urinary retention, bronchospasm, over-sedation, respiratory depression, hypotension, nausea, truncal rigidity, delirium, and immunosuppression. Also, they contribute to vasodilatation and hypotension which lead to increased resuscitation fluids volume in critically ill patient.
"Multi-modal analgesia" also known as "balanced analgesia" approach via using non-opioids adjuvant or in replacement of opioids to target different pain pathways leads to optimizing analgesia and reducing opioids consumption. In France, the second most prescribed non-opioids in mechanically ventilated intensive care unit (ICU) patient is nefopam. Nefopam is a non-opioid, non-steroidal centrally acting analgesic, although the exact mechanism of action poorly understood, analgesic activity is thought to be via inhibiting dopamine, norepinephrine, serotonin reuptake. Nefopam was non-inferior to fentanyl for pain control in patients undergoing elective cardiac surgery without increase in adverse effects. Nefopam has a fentanyl sparing effect up to 50% in patients underwent laparoscopic total hysterectomy.
The 2018 PADIS guideline panel made a conditional recommendation for using "nefopam (if feasible) either as an adjunct or replacement for an opioid to reduce opioid use and their safety concerns for pain management in critically ill adults".
Therefore, the aim of this prospective, randomized, active control, double blinded study is to assess the effect and safety of continuous infusion nefopam in mechanically ventilated ICU patients compared to standard of care. It is being hypothesized that continuous infusion nefopam will reduce opioid use with acceptable safety profile compared to standard of care.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Analgesia, Critical Illness, Mechanical Ventilation, Sedation
Keywords
Nefopam, Ketamine, Standard of care, Sedation, Critically ill, Mechanical ventilation, Propofol, Fentanyl, Midazolam, Delirium, Vasopressors.
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Nefopam group
Arm Type
Experimental
Arm Description
Adjunct continuous infusion of nefopam plus standard of care in ICU for assessment and management of pain, sedation, and delirium.
Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Intervention Type
Drug
Intervention Name(s)
Nefopam
Other Intervention Name(s)
Acupan
Intervention Description
Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
Intervention Type
Drug
Intervention Name(s)
Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Other Intervention Name(s)
Standard of care
Intervention Description
In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
Primary Outcome Measure Information:
Title
Cumulative dose of fentanyl
Description
To compare the cumulative dose of fentanyl
Time Frame
First 24 hour after randomization.
Secondary Outcome Measure Information:
Title
Richmond Agitation and Sedation Score (RASS)
Description
To compare number of patients are in RASS score goal. RASS score minumum -5 (unarousable), maximun +4 (Combative). Goal RASS score from -1 (drowsy) to 0 (alert and calm).
Time Frame
First 24 hours after randomization.
Title
pain score
Description
To compare number of patients are in Pain score goal. If patient able to communicate we use the 0-10 numeric rating scale in a visual format (NRS-V), 0 indicate no pain and 10 indicate the worst pain imaginable.
For patient unable to communicate we use Critical care pain observation tool (CPOT) score, a score ≥3 indicate significant pain.
Time Frame
First 24 hours after randomization.
Title
Duration of mechanical ventilation (MV)
Description
To assess whether nefopam can help to shorten the of being mechanically ventilated.
Time Frame
The number of calendar days from intubation date to extubation date, until ICU discharge, death, or 28 days post-randomization, whichever comes first.
Title
vasopressor requirements
Description
To compare vasopressors requirement
Time Frame
First 24 hours after randomization.
Title
Hemodynamics
Description
changes in Mean Arterial Pressure (MAP) mmHg
Time Frame
First 24 hours after randomization.
Title
Hemodynamics
Description
changes in Heart Rate (HR) beats/minute.
Time Frame
First 24 hours after randomization.
Title
ICU length of stay (LOS)
Description
To compare ICU LOS
Time Frame
From randomization to ICU discharge date
Title
Tracheostomy
Description
Tracheostomy rate
Time Frame
28 days post-randomization
Title
Unplanned extubation (self-extubation)
Description
Unplanned extubation date rate
Time Frame
28 days post-randomization
Title
Re-intubation
Description
Re-intubation rate
Time Frame
28 days post-randomization
Title
Incidence of delirium
Description
Rate of positive confusion assessment method for the ICU (CAM-ICU) score
Time Frame
24 hour after randomization
Title
Use of antipsychotics
Description
Rate of using antipsychotics for confirmed ICU-acquired delirium
Time Frame
24 hour after randomization
Title
Use of physical restraint
Description
Use of physical restraint
Time Frame
24 hour after randomization
Title
Mortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.
Description
Mortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.
Time Frame
28 days after randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients >18 years on mechanical ventilation and expected to need ventilatory support for the next 24 hours.
Candidate for sedation and analgesia protocol
Exclusion Criteria:
Pregnant and/or lactating woman.
Has been intubated for duration longer than 12 hours in an intensive care unit.
Proven or suspected acute primary brain lesion such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury.
Proven or suspected spinal cord injury or other pathology that may result in permanent or prolonged weakness.
Admission as a consequence of a suspected or proven drug overdose
Mean arterial pressure (MAP) < 50 mmHg despite adequate resuscitation and vasopressor therapy at time of randomization.
Death is deemed to be imminent or inevitable during this admission and either the attending physician, patient or substitute decision maker is not committed to active treatment.
Patients with severe hepatic impairment (Child-Pugh class C) or end stage renal disease (ESRD) (creatinine clearance < 30 ml/min or on chronic hemodialysis) due to altered pharmacokinetics [20].
Need for deep sedation such as administration of neuromuscular blockers.
Convulsions or previous history of convulsions.
Risk of urinary retention linked to uretroprostatic disorders.
Risk of acute angle glaucoma.
Known intolerance of or hypersensitivity to study medications or constituents.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mohammed Gamal Abdelraouf Amer, Pharm D
Phone
00201025556853
Email
m.abdelraouf@std.pharma.cu.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohammed Gamal Abdelraouf Amer, Pharm D
Organizational Affiliation
Cairo University Hospitals
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cairo University Hospitals (Kasr Alainy)
City
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohamed Gamal Abdelraouf Amer, Pharm D
Phone
00201025556853
Email
m.abdelraouf@std.pharma.cu.edu.eg
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
18583048
Citation
Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain. 2008 Jul 31;137(3):473-477. doi: 10.1016/j.pain.2008.04.025. Epub 2008 Jun 25. No abstract available.
Results Reference
background
PubMed Identifier
18073576
Citation
Chanques G, Sebbane M, Barbotte E, Viel E, Eledjam JJ, Jaber S. A prospective study of pain at rest: incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit patients. Anesthesiology. 2007 Nov;107(5):858-60. doi: 10.1097/01.anes.0000287211.98642.51. No abstract available.
Results Reference
background
PubMed Identifier
24262016
Citation
Puntillo KA, Max A, Timsit JF, Vignoud L, Chanques G, Robleda G, Roche-Campo F, Mancebo J, Divatia JV, Soares M, Ionescu DC, Grintescu IM, Vasiliu IL, Maggiore SM, Rusinova K, Owczuk R, Egerod I, Papathanassoglou ED, Kyranou M, Joynt GM, Burghi G, Freebairn RC, Ho KM, Kaarlola A, Gerritsen RT, Kesecioglu J, Sulaj MM, Norrenberg M, Benoit DD, Seha MS, Hennein A, Periera FJ, Benbenishty JS, Abroug F, Aquilina A, Monte JR, An Y, Azoulay E. Determinants of procedural pain intensity in the intensive care unit. The Europain(R) study. Am J Respir Crit Care Med. 2014 Jan 1;189(1):39-47. doi: 10.1164/rccm.201306-1174OC.
Results Reference
background
PubMed Identifier
18088561
Citation
Chapman CR, Tuckett RP, Song CW. Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. J Pain. 2008 Feb;9(2):122-45. doi: 10.1016/j.jpain.2007.09.006. Epub 2007 Dec 21.
Results Reference
background
PubMed Identifier
25135146
Citation
Tennant F. The physiologic effects of pain on the endocrine system. Pain Ther. 2013 Dec;2(2):75-86. doi: 10.1007/s40122-013-0015-x. Epub 2013 Aug 20.
Results Reference
background
PubMed Identifier
26308433
Citation
Sigakis MJ, Bittner EA. Ten Myths and Misconceptions Regarding Pain Management in the ICU. Crit Care Med. 2015 Nov;43(11):2468-78. doi: 10.1097/CCM.0000000000001256.
Results Reference
background
PubMed Identifier
20843604
Citation
Chanques G, Viel E, Constantin JM, Jung B, de Lattre S, Carr J, Cisse M, Lefrant JY, Jaber S. The measurement of pain in intensive care unit: comparison of 5 self-report intensity scales. Pain. 2010 Dec;151(3):711-721. doi: 10.1016/j.pain.2010.08.039. Epub 2010 Sep 16.
Results Reference
background
PubMed Identifier
30113379
Citation
Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.
Results Reference
background
PubMed Identifier
16823021
Citation
Gelinas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006 Jul;15(4):420-7.
Results Reference
background
PubMed Identifier
18443635
Citation
Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008 Mar;11(2 Suppl):S105-20.
Results Reference
background
PubMed Identifier
20061837
Citation
Wibbenmeyer L, Sevier A, Liao J, Williams I, Light T, Latenser B, Lewis R 2nd, Kealey P, Rosenquist R. The impact of opioid administration on resuscitation volumes in thermally injured patients. J Burn Care Res. 2010 Jan-Feb;31(1):48-56. doi: 10.1097/BCR.0b013e3181c7ed30.
Results Reference
background
PubMed Identifier
27188977
Citation
Kohler M, Chiu F, Gelber KM, Webb CA, Weyker PD. Pain management in critically ill patients: a review of multimodal treatment options. Pain Manag. 2016 Nov;6(6):591-602. doi: 10.2217/pmt-2016-0002. Epub 2016 May 18.
Results Reference
background
PubMed Identifier
29049119
Citation
Kumar K, Kirksey MA, Duong S, Wu CL. A Review of Opioid-Sparing Modalities in Perioperative Pain Management: Methods to Decrease Opioid Use Postoperatively. Anesth Analg. 2017 Nov;125(5):1749-1760. doi: 10.1213/ANE.0000000000002497.
Results Reference
background
PubMed Identifier
23522398
Citation
Payen JF, Genty C, Mimoz O, Mantz J, Bosson JL, Chanques G. Prescribing nonopioids in mechanically ventilated critically ill patients. J Crit Care. 2013 Aug;28(4):534.e7-12. doi: 10.1016/j.jcrc.2012.10.006. Epub 2013 Mar 19.
Results Reference
background
PubMed Identifier
22711801
Citation
Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11178-83. doi: 10.1073/pnas.1204524109. Epub 2012 Jun 18.
Results Reference
background
PubMed Identifier
24691459
Citation
Kim K, Kim WJ, Choi DK, Lee YK, Choi IC, Sim JY. The analgesic efficacy and safety of nefopam in patient-controlled analgesia after cardiac surgery: A randomized, double-blind, prospective study. J Int Med Res. 2014 Jun;42(3):684-92. doi: 10.1177/0300060514525351. Epub 2014 Apr 1.
Results Reference
background
PubMed Identifier
27103966
Citation
Moon JY, Choi SS, Lee SY, Lee MK, Kim JE, Lee JE, Lee SH. The Effect of Nefopam on Postoperative Fentanyl Consumption: A Randomized, Double-blind Study. Korean J Pain. 2016 Apr;29(2):110-8. doi: 10.3344/kjp.2016.29.2.110. Epub 2016 Apr 1.
Results Reference
background
PubMed Identifier
12421743
Citation
Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1338-44. doi: 10.1164/rccm.2107138.
Results Reference
background
PubMed Identifier
11730446
Citation
Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, Hart RP, Dittus R. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001 Dec 5;286(21):2703-10. doi: 10.1001/jama.286.21.2703.
Results Reference
background
PubMed Identifier
20971961
Citation
Mimoz O, Chauvet S, Gregoire N, Marchand S, Le Guern ME, Saleh A, Couet W, Debaene B, Levy RH. Nefopam pharmacokinetics in patients with end-stage renal disease. Anesth Analg. 2010 Nov;111(5):1146-53. doi: 10.1213/ANE.0b013e3181f33488.
Results Reference
background
PubMed Identifier
14633755
Citation
Du Manoir B, Aubrun F, Langlois M, Le Guern ME, Alquier C, Chauvin M, Fletcher D. Randomized prospective study of the analgesic effect of nefopam after orthopaedic surgery. Br J Anaesth. 2003 Dec;91(6):836-41. doi: 10.1093/bja/aeg264.
Results Reference
background
PubMed Identifier
28215131
Citation
Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, Tidmarsh GF. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc. 2017 Mar;19(1):43-49.
Results Reference
background
Learn more about this trial
Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study
We'll reach out to this number within 24 hrs